The paper evaluates the hypothesis that cannabis abuse is associated with a broad range of psychiatric disorders in India, an area with relatively high prevalence of cannabis use. Retrospective case-note review of all cases with cannabis related diagnosis over a 11 -year period, for subjects presenting to a tertiary psychiatric hospital in southern India was carried out. Information pertaining to sociodemographic, personal, social, substance-use related, psychiatric and treatment histories, was gathered. Standardized diagnoses were made according to Diagnostic Criteria for Research of the World Health Organization, on the basis of information available.
INTRODUCTION
Cannabis is one of the most frequently abused psychoactive drugs (Grinspoon and Bakalar 1993) .
Psychiatric disturbances associated with cannabis use range from minor psychological responses such as anxiety and panic (Thomas 19%) , to depressive disorders (Troisi et al 1998) , the more serious mental illnesses such as the putative 'cannabis psvehosis' (Talbott and Teaguc 1969) , acute functional psvehosis (Johns 21KM), chronic psychosis (Ghodse 1986 ) and the poorly validated entity of '•motivational svndrome (Hall ct al 1999) . The nature of association and the direction of causality between cannabis use and various mental disorders await elucidation (Thomas 1993) . The strongest evidence of a specific contributory role of cannabis use exists only in relation to schizophrenia (Andreasen et al 1987) .
India has a long tradition of cannabis use, which is often socially sanctioned (National Institute of Social Defense 1992). The association between cannabis use and mental disorders has been recorded for well over a century (Indian Hemp Commission Report 1894) . Whilst considerable attention has been paid to the association between cannabis use and psychotic disorders (Basu et al 1999 , Thacore and Shukla 1976 , Chopra and Smith 1974 , relatively little is known about the impact of cannabis abuse on wider psychiatric morbidity. We present a retrospective study as preliminary exploration to evaluate the hypothesis that cannabis abuse will be associated with a broad range of psychiatric disorders, through a case-note review of patients abusing cannabis who presented to a large tertiary psychiatric hospital in south India. We also explored the pattern of cannabis use by this population.
METHODS
The Catchment Population: The study was conducted at a tertiary referral center in Bangalore, catering to a large catchment area. All patients receive a diagnostic code according to the criteria laid down in successive revisions of the International Classification of Diseases -ICD-9, (prior to 1992) and 
RESULTS

Socio-demographic data
Two hundred and forty four notes were identified as having a cannabis related diagnosis. AU 244 subjects were male. Their mean age was 30 years (S.D. ± 9.7; Range = 18-82 years) and 53% were single (109/204; data unrecorded = 40). They had on average 9.7 years (S.D. ± 9.8) of education and 45% had received between 5-10 years of formal education. Sixty-two percent of patients were employed with representation of professional, skilled and unskilled workers being 13%, 27% and 22% respectively.
Substance use history
The mean age of initiation of cannabis use was 22.4 years (S.D. + 8.4 years; Range = 10-65 years). Forty-three percent (9=105 had started using cannabis during the second decades of their lives. Eighty-nine (36%) began use during the third decade whilst twenty-five (10%) did so in the fourth decade. For the rest, onset of use was even later. Where information pertaining to reasons for cannabis use was recorded (n = 115; 47%), 57% cited recreational and experimental use, 12% attributed onset to a dysphoric mood state while 11% cited peer pressure as the primary reason.
Data was unavailable for total duration of non-continuous (regular but not daily) and continuous (daily) cannabis use in 32 (13%o) and 141 (58%) cases respectively. The mean duration of non-continuous use of cannabis was 80 months (S.D. +. 71 months) while the duration of continuous use was 49 months (S.D. ± 50 months). Amongst daily users, 32 (31%) subjects had been using cannabis for less than 2 years, 44 (43 %) patients had been using it between 2-5 years and 27 (26 %) patients had consumed it for over 5 years.
Relation of cannabis use to onset of psychiatric disorders
In 127 patients (52%), a psychiatric disorder had occurred following cannabis use while for 18 patients (7%), psychiatric disturbance had preceded the onset of cannabis use. Data were unavailable for 99 patients (41%). For 67% of patients cannabis was the first drug of abuse in their substance use life-trajectories. Alcohol and opioids were the initial substance of abuse in 29% and 4% patients respectively. Amongst those using cannabis on a continuous basis, 15% also used polysubstance (cannabis, alcohol and opioids for this study) while 11%) and 9% used only alcohol and opioids respectively. Thus, 35% of cannabis users also used other substances concurrendy, whilst for the remaining 65% cannabis remained the only substance of use. Data on homotypic comorbidity (other comorbid substance use disorders) was unavailable for 24 cases (see table 2). Family history Data on family history were available in 202 (83%) subjects. 33 subjects (16%) had a positive family history of a psychiatric disorder and 48 (24%) had a positive family history of substance abuse. Twenty-seven percent of patients with non-psychotic illnesses had a positive family history followed by subjects with affective psychoses (26%), paranoid psychoses including schizophrenia (18%), cannabis psychosis (16%) and substance misuse disorders (9%). Patients with only substance misuse disorders had the highest rate of family history of substance misuse (32%), followed by subjects with non-psychotic illness (29%), paranoid
Psychopathology
Delusional thinking was reported in 105 patients (43%). Persecutory delusions were the commonest (26%) followed by grandiose (22%) and referential (9%) delusions. Fortyone percent of patients experienced hallucinations, most commonly in the auditory modality (25%). Thought disorder, including 'flight of ideas', was recorded in 26 patients (11%). Elated mood (23%) was more common than depressed mood (16%), in patients with affective disturbances. Thought alienation phenomena such as thought broadcasting, thought insertion and thought withdrawal were reported in 11 
Reason for help seeking
For 110 patients (56%) (Data unavailable: n= 47; 19%), display of abnormal behavior usually noted by family members formed the reason for establishing contact with the clinical services. A third of the patients contacted the hospital for relief from distressing withdrawal symptoms of alcohol and opioid withdrawal. Subjectively reported depressed mood was the presenting complaint in 11% patients.
(4%) cases. Increased psychomotor activity (n=ll;4%), pressure of speech (n =9; 3%) and a combination of the two (n=7; 2%) were also evident in a small proportion of patients.. Bizarre behaviour that included such acts as smearing faeces, spitting, inappropriate and vacuous laughter, living in rubbish pits, taking off one's clothes, self mutilation, mutism, and posturing was reported in 31 (13%) cases. Catatonic symptoms were included amongst these. The case notes also recorded ten patients as having clouding of consciousness (4%), and seven patients (3%) with cognitive deficits
Diagnosis
Two types of comorbidity were identified in this cohort. Cannabis use disorder/s was either associated with other substance use disorder/s (but not with substance use related mental disorder/s) or with independent psychiatric disorder/s, i.e. nonsubstance use related. The former was referred to as homotypic while the latter as heterotypic comorbidity [Degenhardt et al 2001] . a) Substance abuse comorbidity (Homotypic comorbidity):
There were in all eight different types of substance related diagnoses, other than cannabis-related diagnoses, in the total cohort (see table 4 ). There were 144 cases of cannabis dependence, 95 cases of harmful use (abuse) and five cases of acute intoxication. One hundred nine patients (47%) also received another substance misuse disorder diagnosis, which included fortynine cases of alcohol abuse (n=23) or dependence (n=26), thirty-six cases of polysubstance abuse (n=13) or dependence (n=23) and thirteen cases of opioid dependence.
Polysubstance abuse/ dependence was recorded in those abusing three different substances concurrendy: cannabis, alcohol and opioids. There were no case of amphetamine, benzodiazepine, cocaine, ecstasy, LSD, inhalant or steroid abuse. The prevalence of nicotine and caffeine use was not recorded. Substance misuse/dependence was the only psychiatric diagnosis in eighty cases (34%). This number may appear to be smaller than what the preceding figures suggest as patient with more than one substance abuse/dependence were counted more than once under the respective headings. For instance a patient with cannabis abuse/dependence who was Heterotypic comorbidity of Cannabis use those with comorbid psychiatric disorders), while 20 patients experienced a non-psychotic illness (12%). The group of patients with psychotic disorders was made up of those suffering with paranoid psychosis including schizophrenia (n=58; 40%), cannabis psychosis (n=51; 35%) and affective psychosis (n=35; 25%). Depressive and anxiety disorders (n=9; 45%) were the largest contributors to the numbers of those with non-psychotic disorders.
Cannabis psychosis was the commonest diagnosis amongst those with psychotic disorders. Six different subtypes of cannabis psychosis were diagnosed, the commonest subtype being a mania-like psychosis (n=22) with grandiose delusions, elated mood and increased psychomotor activity.
A predominandy schizophrenia-like psychotic state (n=8) and a predominandy delusional state (n=6) were seen more often than a further six cases of a predominantly hallucinatory psychosis.
Five subjects presented with a polymorphic and rapidly changing clinical picture characterized by 
I Mixed
Subtypes ol cannabis psychosis
Subtypes of cannabis psychosis
that could be attributed to cannabis abuse. Twelve patients with cannabis psychosis had consumed substances other than cannabis including alcohol (10 cases) and two cases of polysubstance abuse/dependence. These were diagnosed as cannabis psychosis because of a temporal link between cannabis use and onset of psychosis.
Treatment given
About half the patients (49.5%) received antipsychotic medication (49.5%); twentythree patients (9%) received a moodstabilizing agent while 12 (%) were prescribed antidepressants.
(185)
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DISCUSSION
This study has a large patient sample of chronic and heavy cannabis users coming from a wide geographical catchment area including urban, peri-urban, sub-rural, and rural populations.
The sample is representative of all strata of the society. The strengths of the study included data collected at an academic institute with a tradition of good record keeping and diagnostic coding. A manual search in addition to electronic search was carried out to locate all case-notes thereby minimizing the chances of missing cases. Down-rating the aetiologies! role of cannabis in favour of a functional diagnosis would have further reduced any spurious attribution of mental disorders solely to cannabis use.
a) Heterotypic Comorbidity
Our results suggest that heavy and chronic use of cannabis can both cause a cannabisinduced psychosis and be associated with functional psychoses. Broadly, the nature of psychosis associated with heavy cannabis use is non-specific in that it includes both paranoid and affective psychosis but also a polymorphic disorder that cannot be categorized within either of the two groups. A smallet proportion of patients also developed non-psychotic disorders. The presence of a wide variety of psychiatric disorders associated with cannabis abuse therefore confirmed the study hypothesis. The rate of psychiatric morbidity is comparable to earlier reports [Troisi et al 1998, Weller and Halikas 1985] .
b) Cannabis and Manic Psychosis
The most significant finding of the study was the association of cannabis abuse with development of manic disorder. Whilst there are previous smaller reports of a possible association between cannabis use and mania, [Dhunjibhoy 1930 , Rottanburg et al 1982 , Carney et al 1984 , Harding and Knight 1973 we believe that our study is the first one to confirm this relationship in a sizable number of patients. In our cohort, some patients with a past history of mania and cannabis abuse appeared to become sensitized to the effects of cannabis over a period of time so that for subsequent episodes of mania there appeared to be a progressive decrease in the time gap between re-onset of cannabis use and onset of mania.
In other words, the relative shortening of time to relapse following reintroducrion of cannabis use in successive episodes in this select group of patients appeared analogous to the process of 'kindling' [Post et al 1989 , Post et al 1982 . By 'hastening' manic relapses, cannabis appeared to act as a precipitant, akin to the "life-event stressor" first suggested as a triggering mechanism in cases of schizophrenia [Andreasson et al 1987] . The association between cannabis abuse and mania gains further support from a recent study wherein cannabis use during followup of 50 new-onset bipolar disorder patients was associated with the experience of mania, whilst alcohol abuse was linked to the experience of depression [Strakowski et al 2000] .
There may be possible biological explanations for the association between cannabis abuse and mania.
Delta-9-tetrahydrocannabinol (THC), the active ingredient of cannabis, produces euphoria [Brill and Nahas 1984] . Under laboratory conditions high doses of THC have been shown to produce visual and auditory hallucinations, delusions, thought disorder and symptoms of hypomania in normal volunteers [Georgotas and Zeidenberg 1979] . Recent evidence also suggests that cannabinoid receptors, especially CB-1, located in substantia nigra, hippocampus, cerebellum and striatum, may be neuromodulatory by decreasing the uptake of GABA and dopamine, thereby potentiating their actions [D'Souza and Kosten 2001] . Further prospective and case-control studies, which control for other substance misuse are needed to elucidate this further.
ii) Cannabis Psychosis
Our results suggest that besides the triggering effect of cannabis in established bipolar disorders, cannabis psychoses can also present as a manic episode. We also found other psychotic presentations suggesting that cannabis psychosis can present as schizophrenia-like, predominantly delusional or hallucinatory, as affective psychosis or as a polymorphic and rapidly changing psychosis. We could not confirm the previous suggestions that the presence of confusional state is a hallmark of cannabis psychosis [Johns 2001 , Chopra and Smith 1974 , Chaudhry et al 1991 , Tennant and Groesbeck 1972 , Goel and D'Netto 1975 since only three patients in this study displayed a confusional state. The DCR position, which does not prioritize this particular feature to a position of primacy in making a diagnosis of cannabis psychosis, is therefore validated.
iii) Cannabis and Schizophrenic Psychosis
Our results confirm the association between cannabis abuse and paranoid psychoses, especially schizophrenia. However, even some of these cases have prominent affective features, consistent with previous reports [Thacore and Shukla 1976 , Rottanburg et al 1982 , Tsuang et al 1982 . In addition, in a substantial proportion of our cases, only a diagnosis of 'other nonorganic psychotic disorders' (F29 category) [World Health Organization 1993a] could be made on account of bizarre symptomatology, particularly grossly disorganized behavior. Whilst the diagnosis of catatonic schizophrenia had been made for several of these patients by treating clinical teams, this diagnosis was found unsupported by DCR criteria, which specify that catatonic symptoms are not diagnostic of schizophrenia and may be provoked by other aetiologies including alcohol or drugs [World Health Organization 1993b] .
b) Homotypic Comorbidity:
Cannabis has been known as a 'gateway drug', and recent evidence suggests that even after controlling for a wide range of known risk factors for illicit drug use, cannabis use is associated with an increased risk of progression to other illicit drug use [Fergusson and Horwood 2000] . Our study confirms this since many subjects had alcohol, opioid and polysubstance abuse (186) and dependence in this group. Cannabis was die first drug of use in the substance use life-trajectories of two-thirds of this population, the remaining third starting with alcohol or opioids. However, for two-thirds of the whole cohort cannabis remained the only drug of abuse. Whilst this may appear contradictory to the foregoing, we believe diat it is not inconsistent for people to progress from cannabis use to other illicit drugs in experimental ways, but to continue to preferentially use cannabis in a dependant manner, thereby confirming that in countries such as India that have a tradition of cannabis use, the widespread use of other substances is limited [Basu et al 1994] .
The study findings are limited by the cohort being exclusively male, die lack of corroborative urine samples, possible recall bias and under-reporting by patients and, lack of any structured assessments, leading to reliance on case-note data alone.
CONCLUSIONS
Chronic and heavy abuse of cannabis in hospital attending patients in India is associated with widespread psychiatric morbidity. The onset of cannabis use begins at a relatively early age and heralds the experimentation with other psychoactive drugs. For the majority, however, cannabis remains the only drug of abuse. Experience of a psychotic illness is one of the major adverse effects of heavy cannabis use, particularly in those that present to psychiatric hospitals.
Whilst our study confirms some of die earlier findings of association of cannabis use and the development of cannabis psychosis and schizophrenia, most significandy it reveals that heavy cannabis use can specifically cause a mania-like psychosis and more generally act as a precipitant for manic relapse in bipolar patients.
